---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042660"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:56:19.705010+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences FY 2024 net loss narrows to $40.2M; pipeline advancing with multiple data readouts in 2025

## Summary
- Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.
- Cash $112.1M at year-end; projected to fund operations into mid-2026.
- Received $20.1M equity investment and $10M accelerated funding from Gilead.
- Phase 1b data for ABI-4334 (HBV capsid modulator) showed mean 2.9 log10 IU/mL HBV DNA decline in 150mg cohort.
- Interim Phase 1b efficacy data for ABI-5366 and ABI-1179 (genital herpes) expected fall 2025.

## SEC filing metadata
- accession: 0000950170-25-042660
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/0000950170-25-042660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/asmb-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042660
- JSON: https://secwatch.observer/filing/0000950170-25-042660.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.